Ironwood discloses first full quarter of Linzess sales

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) was off $1.12 to $16.77 on Tuesday after the company and partner Forest Laboratories Inc. (NYSE:FRX) reported $4.5 million in net sales in the first full quarter of sales for gastrointestinal drug Linzess linaclotide. The companies launched the guanylate cyclase C ( GCC; GUCY2C) agonist in the U.S. in December to treat irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Forest said it expects Linzess sales of about $170 million for the fiscal year ending March 31, 2014. ...